Literature DB >> 26389665

Non-canonical NF-κB signalling and ETS1/2 cooperatively drive C250T mutant TERT promoter activation.

Yinghui Li1, Qi-Ling Zhou1,2, Wenjie Sun3, Prashant Chandrasekharan4, Hui Shan Cheng1, Zhe Ying5,6, Manikandan Lakshmanan1, Anandhkumar Raju1, Daniel G Tenen2,7, Shi-Yuan Cheng8, Kai-Hsiang Chuang4, Jun Li5,6, Shyam Prabhakar3, Mengfeng Li5,6, Vinay Tergaonkar1.   

Abstract

Transcriptional reactivation of TERT, the catalytic subunit of telomerase, is necessary for cancer progression in about 90% of human cancers. The recent discovery of two prevalent somatic mutations-C250T and C228T-in the TERT promoter in various cancers has provided insight into a plausible mechanism of TERT reactivation. Although the two hotspot mutations create a similar binding motif for E-twenty-six (ETS) transcription factors, we show that they are functionally distinct, in that the C250T unlike the C228T TERT promoter is driven by non-canonical NF-κB signalling. We demonstrate that binding of ETS to the mutant TERT promoter is insufficient in driving its transcription but this process requires non-canonical NF-κB signalling for stimulus responsiveness, sustained telomerase activity and hence cancer progression. Our findings highlight a previously unrecognized role of non-canonical NF-κB signalling in tumorigenesis and elucidate a fundamental mechanism for TERT reactivation in cancers, which if targeted could have immense therapeutic implications.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26389665      PMCID: PMC4772727          DOI: 10.1038/ncb3240

Source DB:  PubMed          Journal:  Nat Cell Biol        ISSN: 1465-7392            Impact factor:   28.824


  68 in total

1.  Molecular biology. Wnt regulates TERT--putting the horse before the cart.

Authors:  Carol W Greider
Journal:  Science       Date:  2012-06-22       Impact factor: 47.728

Review 2.  The role of telomeres in stem cells and cancer.

Authors:  Cagatay Günes; K Lenhard Rudolph
Journal:  Cell       Date:  2013-01-31       Impact factor: 41.582

3.  Quantitation of telomerase components and hTERT mRNA splicing patterns in immortal human cells.

Authors:  X Yi; J W Shay; W E Wright
Journal:  Nucleic Acids Res       Date:  2001-12-01       Impact factor: 16.971

4.  Dendritic cells require the NF-kappaB2 pathway for cross-presentation of soluble antigens.

Authors:  Evan F Lind; Cory L Ahonen; Anna Wasiuk; Yoko Kosaka; Burkhard Becher; Kathy A Bennett; Randolph J Noelle
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

5.  Telomeres shorten during ageing of human fibroblasts.

Authors:  C B Harley; A B Futcher; C W Greider
Journal:  Nature       Date:  1990-05-31       Impact factor: 49.962

6.  ETS transcription factor ESE1/ELF3 orchestrates a positive feedback loop that constitutively activates NF-κB and drives prostate cancer progression.

Authors:  Nicole Longoni; Manuela Sarti; Domenico Albino; Gianluca Civenni; Anastasia Malek; Erica Ortelli; Sandra Pinton; Maurizia Mello-Grand; Paola Ostano; Gioacchino D'Ambrosio; Fausto Sessa; Ramon Garcia-Escudero; George N Thalmann; Giovanna Chiorino; Carlo V Catapano; Giuseppina M Carbone
Journal:  Cancer Res       Date:  2013-05-16       Impact factor: 12.701

7.  A NIK-IKKα module expands ErbB2-induced tumor-initiating cells by stimulating nuclear export of p27/Kip1.

Authors:  Weizhou Zhang; Wei Tan; Xuefeng Wu; Maxim Poustovoitov; Amy Strasner; Wei Li; Nicholas Borcherding; Majid Ghassemian; Michael Karin
Journal:  Cancer Cell       Date:  2013-04-18       Impact factor: 31.743

8.  NF-κB inducing kinase (NIK) modulates melanoma tumorigenesis by regulating expression of pro-survival factors through the β-catenin pathway.

Authors:  Y M Thu; Y Su; J Yang; R Splittgerber; S Na; A Boyd; C Mosse; C Simons; A Richmond
Journal:  Oncogene       Date:  2011-10-03       Impact factor: 9.867

9.  Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) promotes glioma cell invasion through induction of NF-κB-inducing kinase (NIK) and noncanonical NF-κB signaling.

Authors:  Evan M Cherry; Dong W Lee; Ji-Ung Jung; Raquel Sitcheran
Journal:  Mol Cancer       Date:  2015-01-27       Impact factor: 27.401

10.  Generation of mutant mice by pronuclear injection of circular plasmid expressing Cas9 and single guided RNA.

Authors:  Daisuke Mashiko; Yoshitaka Fujihara; Yuhkoh Satouh; Haruhiko Miyata; Ayako Isotani; Masahito Ikawa
Journal:  Sci Rep       Date:  2013-11-27       Impact factor: 4.379

View more
  85 in total

Review 1.  The ETS family of oncogenic transcription factors in solid tumours.

Authors:  Gina M Sizemore; Jason R Pitarresi; Subhasree Balakrishnan; Michael C Ostrowski
Journal:  Nat Rev Cancer       Date:  2017-04-28       Impact factor: 60.716

2.  Association of TERT promoter mutations with telomerase expression in melanoma.

Authors:  Seungjae Lee; Patricia Opresko; Alberto Pappo; John M Kirkwood; Armita Bahrami
Journal:  Pigment Cell Melanoma Res       Date:  2016-05       Impact factor: 4.693

Review 3.  When the Ends Are Really the Beginnings: Targeting Telomerase for Treatment of GBM.

Authors:  Saumya R Bollam; Michael E Berens; Harshil D Dhruv
Journal:  Curr Neurol Neurosci Rep       Date:  2018-03-10       Impact factor: 5.081

4.  TERT promoter mutations in melanoma survival.

Authors:  Eduardo Nagore; Barbara Heidenreich; Sívaramakrishna Rachakonda; Zaida Garcia-Casado; Celia Requena; Virtudes Soriano; Christoph Frank; Victor Traves; Esther Quecedo; Josefa Sanjuan-Gimenez; Kari Hemminki; Maria Teresa Landi; Rajiv Kumar
Journal:  Int J Cancer       Date:  2016-03-02       Impact factor: 7.396

5.  Telomerase reverse transcriptase promotes cancer cell proliferation by augmenting tRNA expression.

Authors:  Ekta Khattar; Pavanish Kumar; Chia Yi Liu; Semih Can Akıncılar; Anandhkumar Raju; Manikandan Lakshmanan; Julien Jean Pierre Maury; Yu Qiang; Shang Li; Ern Yu Tan; Kam M Hui; Ming Shi; Yuin Han Loh; Vinay Tergaonkar
Journal:  J Clin Invest       Date:  2016-09-19       Impact factor: 14.808

6.  SDHD Promoter Mutations Ablate GABP Transcription Factor Binding in Melanoma.

Authors:  Tongwu Zhang; Mai Xu; Matthew M Makowski; Christine Lee; Michael Kovacs; Jun Fang; Esther Willems; Jeffrey M Trent; Nicholas K Hayward; Michiel Vermeulen; Kevin M Brown
Journal:  Cancer Res       Date:  2017-01-20       Impact factor: 12.701

7.  Repression of telomerase gene promoter requires human-specific genomic context and is mediated by multiple HDAC1-containing corepressor complexes.

Authors:  Yuanjun Zhao; Shuwen Wang; Fan Zhang; Mariano Russo; Steven B McMahon; Jiyue Zhu
Journal:  FASEB J       Date:  2016-12-09       Impact factor: 5.191

8.  Merkel Cell Polyomavirus Small T Antigen Activates Noncanonical NF-κB Signaling to Promote Tumorigenesis.

Authors:  Jiawei Zhao; Yuemeng Jia; Shunli Shen; Jiwoong Kim; Xun Wang; Eunice Lee; Isaac Brownell; Jeong Hee Cho-Vega; Cheryl Lewis; Jade Homsi; Rohit R Sharma; Richard C Wang
Journal:  Mol Cancer Res       Date:  2020-08-04       Impact factor: 5.852

Review 9.  New prospects for targeting telomerase beyond the telomere.

Authors:  Greg M Arndt; Karen L MacKenzie
Journal:  Nat Rev Cancer       Date:  2016-06-24       Impact factor: 60.716

Review 10.  Understanding TERT Promoter Mutations: A Common Path to Immortality.

Authors:  Robert J A Bell; H Tomas Rube; Ana Xavier-Magalhães; Bruno M Costa; Andrew Mancini; Jun S Song; Joseph F Costello
Journal:  Mol Cancer Res       Date:  2016-03-03       Impact factor: 5.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.